Evidence map›Paper›PMID 41392951›Full record

ArticleJournal of comparative effectiveness research2026

Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison.

Todd Bauer, Devin Abrahami, Anna Polli, Haitao Chu, Priya Ramachandran, Conor Chandler, Min Tan, James Truscott, Julien Mazieres, Christine A Garcia

Abstract readComparative Study
In one paragraph

Article in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Todd BauerGreco-Hainsworth Centers for Research/Tennessee Oncology, PLLC, Franklin, TN 37067, USA.
Devin AbrahamiPfizer Inc, New York, NY 10001, USA.
Anna PolliPfizer Inc, New York, NY 10001, USA.
Haitao ChuPfizer Inc, New York, NY 10001, USA.
Priya RamachandranPfizer Inc, New York, NY 10001, USA.
Conor ChandlerThermo Fisher Scientific, Waltham, MA 02451, USA.
Min TanThermo Fisher Scientific, Waltham, MA 02451, USA.
James TruscottThermo Fisher Scientific, Waltham, MA 02451, USA.
Julien MazieresToulouse University Hospital, Institut Universitaire du Cancer, France.
Christine A GarciaDepartment of Medicine, Weill Cornell Medicine & New York Presbyterian Hospital, New York, NY 10065, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AminopyridinesCarbazolesCarcinoma, Non-Small-Cell LungLactams, MacrocyclicLung NeoplasmsPiperidinesProtein Kinase InhibitorsAdultAgedAnaplastic Lymphoma KinaseFemaleHumansLactamsMaleMiddle AgedProgression-Free SurvivalalectinibALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseCarbazolesLactamsLactams, MacrocycliclorlatinibPiperidinesProtein Kinase InhibitorsPyrazolesalectinibindirect treatment comparisonlorlatinibnext-generation ALK TKInon-small cell lung cancerprogression-free survival

Identifiers

PMID41392951
PMCPMC12711101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.